Adalvo Files For Generic Version Of Takeda’s Firazyr
Seeks EMA’s Approval For Icatibant Pre-filled Syringe
Alvogen’s newly created B2B unit, Adalvo, has filed for a generic version of Takeda’s Firazyr with the EMA to enhace its peptide portfolio, which currently includes several products focused on rare diseases and diabetes. Adalvo believes it is in the first wave of applicants to submit its filing within the European Union.
